Medicare Enrolled
Dr. Scott Schneiderman, D.O.
Family Medicine · Monterey, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Schneiderman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Schneiderman?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Schneiderman
Dr. Scott Schneiderman is a family medicine specialist in Monterey, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Schneiderman performed 2,775 Medicare services across 551 unique beneficiaries.
Between the years covered by Open Payments, Dr. Schneiderman received a total of $17,295 from 68 pharmaceutical and/or device companies across 558 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in family medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Schneiderman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 7% volume in CA
$17,295 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,775
Medicare services
Top 7% in CA for family medicine
551
Unique beneficiaries
$46
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~146 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 1,140 | $17 | $22 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
547 | $95 | $150 |
| Home visit, established patient, moderate complexity A home visit for an established patient involving moderate medical decision making. The visit requires at least 40 minutes of time if time is used to determine the level of service. |
285 | $102 | $190 |
| Home visit, established patient, low complexity A physician visits an existing patient at their residence to provide care involving a low level of medical decision making. The visit lasts at least 30 minutes. |
197 | $52 | $130 |
| Blood glucose test using hand-held instrument A test that measures the level of sugar in the blood using a portable device. The result helps monitor blood glucose levels. |
166 | $3 | $6 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
140 | $11 | $45 |
| Hemoglobin a1c level, by device for home use | 104 | $10 | $25 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
67 | $69 | $125 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
34 | $0 | $8 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
24 | $132 | $175 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
22 | $46 | $65 |
| Home visit, new patient, moderate complexity A home visit for a new patient involving moderate medical decision making, lasting at least 60 minutes. |
20 | $117 | $270 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
16 | $136 | $200 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
13 | $2 | $6 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$17,295
Total received (2018-2024)
Avg $2,471/year across 7 years
Top 2% in CA for family medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
68
Companies
558
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,184 (64.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$6,111 (35.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,215
2023
$1,744
2022
$1,921
2021
$1,782
2020
$1,756
2019
$1,184
2018
$7,692
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$293
Edwards Lifesciences Corporation
$220
GlaxoSmithKline, LLC.
$165
Lilly USA, LLC
$110
Amgen Inc.
$78
Braeburn Inc.
$69
Philips North America LLC
$53
VIVUS LLC
$49
ABBVIE INC.
$36
Mylan Specialty L.P.
$31
Lundbeck LLC
$28
Otsuka Pharmaceutical Development & Commercialization, Inc.
$28
Indivior Inc.
$23
ACADIA Pharmaceuticals Inc
$19
Esperion Therapeutics, Inc.
$15
Top 3 companies account for 55.8% of 2024 payments
All-time payments by company (2018-2024) ›
Indivior Inc.
$6,273
GlaxoSmithKline, LLC.
$1,006
Boehringer Ingelheim Pharmaceuticals, Inc.
$934
Amgen Inc.
$800
Janssen Pharmaceuticals, Inc
$739
Avanir Pharmaceuticals, Inc.
$655
AbbVie Inc.
$633
AstraZeneca Pharmaceuticals LP
$400
Harmony Biosciences LLC
$390
Allergan, Inc.
$361
PFIZER INC.
$286
Collegium Pharmaceutical, Inc.
$253
Lilly USA, LLC
$243
ABBVIE INC.
$239
HARMONY BIOSCIENCES LLC
$221
Edwards Lifesciences Corporation
$220
Boston Scientific Corporation
$214
Merck Sharp & Dohme LLC
$195
Regeneron Healthcare Solutions, Inc.
$191
ACADIA Pharmaceuticals Inc
$177
Novo Nordisk Inc
$173
Mylan Specialty L.P.
$162
Abbott Laboratories
$161
Daiichi Sankyo Inc.
$146
Bayer HealthCare Pharmaceuticals Inc.
$126
Esperion Therapeutics, Inc.
$111
Allergan Inc.
$110
ITI, Inc.
$108
Sunovion Pharmaceuticals Inc.
$108
Takeda Pharmaceuticals U.S.A., Inc.
$96
Otsuka America Pharmaceutical, Inc.
$96
Teva Pharmaceuticals USA, Inc.
$95
AbbVie, Inc.
$94
Braeburn Inc.
$90
Radius Health, Inc.
$76
Nuvectra Corporation
$74
Biohaven Pharmaceuticals, Inc.
$74
Merck Sharp & Dohme Corporation
$69
E.R. Squibb & Sons, L.L.C.
$54
Philips North America LLC
$53
Lundbeck LLC
$49
VIVUS LLC
$49
Bausch Health US, LLC
$44
Corcept Therapeutics
$42
Aytu Bioscience, Inc
$42
Xeris Pharmaceuticals, Inc.
$38
MannKind Corporation
$38
Kowa Pharmaceuticals America, Inc.
$37
Titan Pharmaceuticals, Inc.
$35
Alfasigma USA, Inc.
$33
GRT US Holding, Inc.
$33
Philips Electronics North America Corporation
$32
BioDelivery Sciences International, Inc.
$31
Zyla Life Sciences
$30
Otsuka Pharmaceutical Development & Commercialization, Inc.
$28
iRhythm Technologies, Inc.
$25
Amarin Pharma Inc.
$23
Insulet Corporation
$21
Alkermes, Inc.
$20
Vertos Medical, Inc.
$19
Sentynl Therapeutics, Inc.
$18
Acerus Pharmaceuticals Corporation
$18
RedHill Biopharma Inc.
$17
BOSTON SCIENTIFIC CORPORATION
$17
Sanofi Pasteur Inc.
$16
Alnylam Pharmaceuticals Inc.
$15
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$11
Romark Laboratories, LC
$8
Top 3 companies account for 47.5% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (9369) Reusable Vest · AFREZZA · AIRSUPRA · AJOVY · ANORO · ANORO ELLIPTA · APLENZIN · AREXVY · Aciphex · Aimovig · Algovita · Alinia Tablets 500mg 30 count bottle · Amitiza · BELSOMRA · BEVESPI AEROSPHERE · BRIXADI · BUNAVAIL 2.1 mg 30-count box · BYSTOLIC · CAPLYTA · CHANTIX · COLOGUARD DNA CAPTURE REAGENTS · Creon · EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) · ELIQUIS · EUCRISA · EVENITY · FARXIGA · FLUZONE HIGH-DOSE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · GENERAL - PAIN MANAGEMENT · GENERAL PAIN MANAGEMENT · GIVLAARI · GVOKE PFS · INJECTAFER · INVOKANA · JARDIANCE · Kerendia · Korlym · LINZESS · LONHALA MAGNAIR · LYRICA · Levorphanol · Livalo · MOUNJARO · Morphabond ER · Movantik · NEXLETOL · NUEDEXTA · NUPLAZID · NURTEC ODT · Natesto · Nuedexta · Omnipod · Otezla · Ozempic · PANCREAZE · PRALUENT · PRALUENT ALIROCUMAB INJECTION · Probuphine · Prolia · QULIPTA · Qutenza · REXULTI · RYBELSUS · Repatha · Rybelsus · SAPIEN 3 Ultra RESILIA · SPECTRA WAVEWRITER · SPIRIVA · SPIRIVA RESPIMAT · SPRIX · STIOLTO RESPIMAT · SUBLOCADE · SUBOXONE SUBLINGUAL FILM · SUPERION · Seglentis · TRADJENTA · TRELEGY ELLIPTA · TRINTELLIX · Trintellix · Tymlos · UBRELVY · VERQUVO · VIBERZI · VIIBRYD · VRAYLAR · Vascepa · Vivitrol 380 mg · WAKIX · WAVEWRITER ALPHA · Wakix · WaveWriter Alpha Prime 16 · XARELTO · XIFAXAN · XTAMPZA · YUPELRI · Yupelri · ZIO XT Patch · mild Device Kit
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (65%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 2% for family medicine in CA.
Geographic Context
Family medicine physicians within 10 mi
232
Per 100K population
53.2
County median income
$94,486
Nearest hospital
COMMUNITY HOSPITAL OF THE MONTEREY PENINSULA
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Schneiderman is a clinical cardiology specialist, with above-average Medicare volume (top 7% in CA), with low-engagement industry engagement in the top 2% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Schneiderman experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Schneiderman performed 1,140 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Schneiderman receive payments from pharmaceutical companies?
Yes. Dr. Schneiderman received a total of $17,295 from 68 companies across 558 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Schneiderman's costs compare to other family medicine physicians in Monterey?
Dr. Schneiderman's average Medicare payment per service is $46. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Schneiderman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Family Medicine
Common procedures, typical costs, and what industry payments mean in family medicine.
Same specialty & city
Family Medicine Physicians in Monterey
Browse family medicine physicians in Monterey ranked by procedure volume and transparency data.
Highest volume
Top Family Medicine Physicians in CA
Family medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Family Medicine Physicians in CA
Which CA family medicine physicians receive the most from drug and device companies.
By company
Indivior Inc. Payments to Doctors
See all physicians who received payments from Indivior Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology